Trial Profile
An Open-Label, Dose Ranging, Randomized Clinical Evaluation of OPT-80 in Patients With Clostridium Difficile-Associated Diarrhea (CDAD)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 13 Dec 2023
Price :
$35
*
At a glance
- Drugs Fidaxomicin (Primary)
- Indications Clostridium difficile infections; Diarrhoea
- Focus Therapeutic Use
- Sponsors Optimer Pharmaceuticals
- 24 Mar 2009 New trial record.